

*Bef Seq
I FWJ*



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Daria ONICHTCHOUK et al.

Examiner: Unassigned

Serial No.: 10/564,769

Group Art Unit: Unassigned

Filed: January 17, 2006

Title: USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME

REQUEST FOR WITHDRAWAL OF IMPROPER HOLDING OF ABANDONMENT

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In view of the following documents, it is unambiguous that Applicants filed a complete response to the missing parts notice dated April 11, 2006. This response was filed on June 12, 2006.

Attached is a copy of the firm's Official PTO filing record notebook for the day of June 12, 2006. Listed in association with the firm's docket number for the above-identified application, "Weickm-0053," is the entry "NTFMR; Decl & POA; Assign; Ck#37127 \$40.00; Record Cover Sheet; Seq. listing w/disk ck#37126 \$65.00." This means that being filed is a response to the notice to file missing requirements; a declaration and a power of attorney; an

assignment (ck#37127 for \$40.00); a recordation cover sheet for the assignment; a sequence listing with disk along with ck#37126 for \$65.00.

The initials in our rightmost margins refer to various personnel who have checked the filing to be sure all papers were present.

Further evidence that these papers were filed is the accompanying PTO Notice of Recordation of Assignment document. This notes a recordation date of June 15, 2006, consistent with the filing of the papers on June 12, 2006.

Further evidence that the papers were filed is the fact that both checks mentioned in the firms PTO docket entry book were cashed by the PTO. See the accompanying papers which establish this fact.

Accordingly, more than sufficient evidence is believed to be provided, whereupon the PTO should withdraw the holding of abandonment as improper and restore this application to pending status in view of the accompanying papers, which are identical to those previously filed.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: WEICKM-0053

Date: August 4, 2008

AJZ:pdr


MONDAY

12

JUNE

H/C	Case No.	Papers Filed	Sec Y/N Paid
NO	PLORIN-0001-A-C01	IDS; PTO 1449; 1Ref	✓ DD ✓ dd
NO	PLORIN-0002-A	IDS; PTO 1449; 1Ref CR#36983 \$180.00	✓ DD ✓ dd
NO	GKSS-6004	Notice of Appeal 2mo EOT CL 950.00 36984	✓ DD ✓ dd
NO	UNIMD-11	NEW USNP; Transmittal; Appl. (208 pgs); SR ✓	✓ DD ✓ dd
NO	Oscorp 1	IDS; PTO 1449; CR# 37123 \$825.00	✓ DD ✓ dd
NO	Entex IC 1	Issue fee & Pub. fee \$1000 # 37133	✓ DD ✓ dd
NO	Steh 1714 A D1	Reply & CR#(1) \$250 # 37134	✓ DD ✓ dd
NO	Emic-0054	NOA; 2mo EOT; CR# 37168-37167	DD ✓ dd
NO	Bayer-001/C01	Reply; 1mo EOT; CR# 36880	DD ✓ dd
NO	MERCK-2868	Reply	DD ✓ dd
NO	MERCK-2904	Prelim Ext Reply w/CR#458.00	DD ✓ dd
NO	MERCK-3177	New USNP; Transmittal; Appl. (110 pgs) SR ✓	DD ✓ dd
		prelim Am; Decl; Assign; IDS; PTO 1449; CR# 37124 \$1000; CR# 37125 \$40	DD ✓ dd
NO	Merck-2975	Not to comply; seq listing w/ disk	DD ✓ dd
NO	Merck-3171	IDS w/PTO-1449	DD ✓ dd
NO	Weickm-53	NTFHR; Decl & POA; Assign; Record. Cover CR# 37127 \$40.00 sheet; Seq. listing w/ disk CR# 37126 \$65.00	DD ✓ dd
NO	Royal-4	Reply; Exhibits w/ 6 Sheets	DD ✓ dd

A5 w/ cover	Merck-3183	New US; Transmittal; Prelim Am; SR ✓ App (25 pgs) Pri. doc w/ transmittal; IDS; PTO-1449
A5 w/ cover	MERCK-2647	Preliminary Amendment in Resp. to Notice of Non-compliant amendment HW ✓



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

JULY 26, 2006

PTAS

MILLEN, WHITE ZELANO & BRANIGAN, P.C.
ARLINGTON COURT PLAZA I
SUITE 1400
2200 CLARENDON BLVD.
ARLINGTON, VA 22201



103261547A

Wickum-53

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF
THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS
AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER
REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE
INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA
PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD
FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY
CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 571-272-3350.
PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE,
MAIL STOP: ASSIGNMENT SERVICES BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/15/2006

REEL/FRAME: 018001/0835

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
ONICHTCHOUK, DARIA

DOC DATE: 02/20/2006

ASSIGNOR:
BURK, ULRIKE

DOC DATE: 02/13/2006

ASSIGNEE:
DEVELOGEN AKTIENGESELLSCHAFT
MARIE-CURIE-STR. 7
GOETTINGEN, GERMANY 37079

SERIAL NUMBER: 10564769

FILING DATE:

PATENT NUMBER:

ISSUE DATE:

TITLE: USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES
AND/OR OBESITY AND/OR METABOLIC SYNDROME

[Handwritten signature]

018001/0835 PAGE 2

SHARON LATIMER, EXAMINER
ASSIGNMENT SERVICES BRANCH
PUBLIC RECORDS DIVISION

6-15-06
U U
RECORDATION FORM COVEI
PATENTS ONLY


06-21-2006


103261547

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below..

1. Name of conveying party(ies):

Daria ONICHTCHOUK
Ulrike BURK



2. Name and address of receiving party(ies):

Name: DeveloGen Aktiengesellschaft

Street Address: Marie-Curie-Str. 7

City: Goettingen

State: GERMANY

Zip: 37079

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of Conveyance/Execution Date(s):

Execution Date(s): February 20, 2006; February 13, 2006

- Assignment Merger
 Security Agreement Change of Name
 Joint Research Agreement
 Government Interest Assignment
 Executive Order 9424, Confirmatory License
 Other

Additional names(s) or address(es) attached? Yes No

4. Application or patent number(s): This document is being filed together with a new application.

A. Patent Application No.(s)

B. Patent No.(s)

06/15/2006 MKAYPAGH 00000038 10564796
02 FC:8.21

10/564,769 Additional numbers attached? Yes No
40.00 DP

5. Name and address to whom correspondence concerning document should be mailed:

Name: MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Address: Arlington Court Plaza I
Suite 1400
2200 Clarendon BLVD.
Arlington, VA 22201
Phone: (703) 243-6333
Fax: (703) 243-6410
E-Mail: mail@mwbz.com

6. Total number of applications and patents involved: 1

7. Total fee (37CFR 1.21(h) AND 3.41) \$40.00

- Authorized to be charged by credit card
 Authorized to be charged to deposit account
 Enclosed
 None required (government interest not affecting title)

8. Payment Information

- a) Credit Card Last 4 Numbers
Expiration Date
b) Deposit Account Number 13-3402
Authorized User Name

9. Signature.

Signature

Anthony J. Zelano

Date

Anthony J. Zelano
Name of Person Signing

Attorney Docket No. WEICKM-53

Total number of pages including cover sheet, attachments, and documents 2

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
PATENT OFFICE FEES ACCOUNT
2200 CLARENDON BOULEVARD, SUITE 1400
ARLINGTON, VIRGINIA 22201

BRANCH BANKING AND TRUST COMPANY
ARLINGTON, VIRGINIA
68-426/514

37127

6/12/2006

PAY TO THE COMMISSIONER OF PATENTS AND TRADEMARKS

40.00


Forty & No/100 Dollars

\$

DOLLARS

WEICKM-0053

MEMO _____




MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
PATENT OFFICE FEES ACCOUNT
2200 CLARENDON BOULEVARD, SUITE 1400
ARLINGTON, VIRGINIA 22201

BRANCH BANKING AND TRUST COMPANY
ARLINGTON, VIRGINIA
68-426/514

37126

6/12/2006

PAY TO THE COMMISSIONER OF PATENTS AND TRADEMARKS

65.00

Sixty-Five & No/100 Dollars

\$

DOLLARS

WEICKM-0053

MEMO _____




PATENT AND TRADEMARK OFFICE
13-10-0001
06-15-2006
FOR CREDIT TO THE
U.S. TREASURY

PATENT AND TRADEMARK OFFICE
13-10-0001
06-15-2006
FOR CREDIT TO THE
U.S. TREASURY

1068961180
NO312007304
PHILA, PA 06192006 09/91
MACHINERY MFG CO INC
PK166
66200006
13441

1068961180
NO312007304
PHILA, PA 06192006 09/91
MACHINERY MFG CO INC
PK166
66200006
13441

1068961180
NO312007304
PHILA, PA 06192006 09/91
MACHINERY MFG CO INC
PK166
66200006
13441

1068961180
NO312007304
PHILA, PA 06192006 09/91
MACHINERY MFG CO INC
PK166
66200006
13441



SEQUENCE LISTING

<110> DeveloGen AG für entwicklungsbiologische Forschung
<120> Use of a DG001 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
<130> 31160PWO_GE
<140> PCT/EP2004/007917
<141> 2004-07-15
<150> EP03016169.9
<151> 2003-07-16
<160> 5
<170> PatentIn Ver. 2.1
<210> 1
<211> 1300
<212> DNA
<213> human

<220>
<221> gene
<222> (1)..(1300)
<223> nucleic acid sequence encoding the human DG001 protein

<400> 1
ctctccctcc ctgcggccagc cttcgtcctc ctggccccgt cctctcatcc ctcccattct 60
ccatttccct tccggttccct ccctgtcagg gcgttaattga gtcaaaaggca ggatcagggtt 120
ccccgccttc cagtccaaaa atcccccaa gagagccca gagcagagga aaatccaaag 180
tggagagagg ggaagaaaaga gaccagttag tcatccgtcc agaaggcggg gagagcagca 240
gcggcccaag caggagactgc agcgagccgg gtacctggac tcagcggtag caacctcgcc 300
ccttgcaca aaggcagact gagcgcaga gaggacgtt ccaactcaa aatgcaggct 360
caacagtacc agcagcagcg tcgaaaattt gcagctgcct tcttggcatt cattttcata 420
ctggcagctg tggatactgc tgaagcaggg aagaaaagaga aaccagaaaa aaaagtgaag 480
aagtctgact gtggagaatg gcagtggagt gtgtgtgtgc ccaccagtgg agactgtggg 540
ctgggcacac gggaggcgcac tcggactgga gctgagtgca agcaaaccat gaagaccagg 600
agatgttaaga tcccctgcaa ctggagaag caatttggcg cggagtgcaa ataccagttc 660
caggcctggg gagaatgtga cctgaacaca gccctgaaga ccagaactgg aagtctgaag 720
cgagccctgc acaaatgccga atgccagaag actgtcacca tctccaagcc ctgtggcaaa 780
ctgaccaagc ccaaaccctca agcagaatct aagaagaaga aaaaggaagg caagaaacag 840
gagaagatgc tggattaaaa gatgtcacct gtggacacata aaaaggacat cagcaaacag 900
gatcagttaa ctattgcatt tatatgtacc gtaggcttg tattcaaaaa ttatctatag 960
ctaagtacac aataagcaaa aacaaaaaga aaagaaaatt ttgttagtag cgtttttaa
1020
atgtatacta tagtaccagt aggggcttat aataaaggac tgtaatctta tttaggaagt
1080
tgacttatag tacatgataa atgatagaca attgaggtaa gtttttgaa attatgtgac
1140
attttacatt aaatttttt tacattttt gggcagcaat ttaaatgtta tgactatgt
1200
aactacttct cttgttaggt aattttttc acctagattt tttcccaat tgagaaaaat
1260
atatactaaa caaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1300

<210> 2
<211> 168
<212> PRT
<213> human

<220>
<223> amino acid sequence of human DG001 protein

<400> 2
Met Gln Ala Gln Gln Tyr Gln Gln Arg Arg Lys Phe Ala Ala Ala
1 5 10 15

Phe Leu Ala Phe Ile Phe Ile Leu Ala Ala Val Asp Thr Ala Glu Ala
20 25 30

Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys Ser Asp Cys Gly
35 40 45

Glu Trp Gln Trp Ser Val Cys Val Pro Thr Ser Gly Asp Cys Gly Leu
50 55 60

Gly Thr Arg Glu Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met
65 70 75 80

Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys Lys Gln Phe Gly
85 90 95

Ala Glu Cys Lys Tyr Gln Phe Gln Ala Trp Gly Glu Cys Asp Leu Asn
100 105 110

Thr Ala Leu Lys Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn
115 120 125

Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro Cys Gly Lys Leu
130 135 140

Thr Lys Pro Lys Pro Gln Ala Glu Ser Lys Lys Lys Lys Glu Gly
145 150 155 160

Lys Lys Gln Glu Lys Met Leu Asp
165

<210> 3
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 5`-3

<220>
<223> mouse DG001 forward primer

<400> 3
caagtaccag ttccaggctt gg 22

<210> 4
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer 5`-3

<220>
<223> mouse DG001 reverse primer

<400> 4
gctcgcttca ggctgcc

17

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: probe

<220>
<223> mouse DG001 Taqman probe

<400> 5
tgacctcaat accgccttga agaccagaac

30